secwatch.observer — SEC 8-K summary
======================================

Issuer:     Equillium, Inc. (EQ)
CIK:        0001746466
Form:       8-K
Filed at:   2026-08-13T20:10:16+00:00
Accession:  0001193125-26-349182
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Equillium Q2 2026 net loss $4.7M; cash $57.2M funds operations into 2029
------------------------------------------------------------------------

- Net loss $4.7M ($0.04/share) vs $5.7M ($0.16/share) in Q2 2025; R&D spend down to $2.8M from $4.1M.
- Cash and equivalents $57.2M at June 30, 2026, down from $61.3M at March 31, 2026; runway into 2029.
- EQ504 Phase 1 proof-of-mechanism study expected to start Q4 2026; topline data ~6 months later.
- IND-enabling work initiated for inhaled EQ504 (lung disease) and oral EQ302 (celiac disease).
- Clinical Advisory Board for EQ504 ulcerative colitis program chaired by Prof. Bruce Sands (Mount Sinai).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1746466/000119312526349182/0001193125-26-349182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1746466/000119312526349182/eq-20260813.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-349182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer